Chengdu Kanghong Biotech Co., Ltd.

4 in Phase 3

Quick facts

Phase 3 pipeline

conbercept, Fixed · Ophthalmology
Conbercept is a recombinant human VEGF decoy receptor that inhibits angiogenesis.
Conbercept ophthalmic injection · Ophthalmology
Conbercept is a recombinant fusion protein that binds and neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to inhibit pathological neovascularization in the eye.
conbercept, PRN · Ophthalmology
Conbercept is a recombinant fusion protein that acts as a soluble decoy receptor to bind and neutralize vascular endothelial growth factor (VEGF) and placental growth factor (PlGF).
Placebo + Paclitaxel · Oncology
Paclitaxel works by inhibiting cell division, thereby preventing cancer cells from growing and dividing.

Phase 2 pipeline

Intravitreal injection of KH902 · Ophthalmology
KH902 is a recombinant fusion protein that inhibits vascular endothelial growth factor (VEGF) signaling to reduce abnormal blood vessel growth and vascular permeability in the eye.

Phase 1 pipeline

KH902

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Chengdu Kanghong Biotech Co., Ltd.

What is Chengdu Kanghong Biotech Co., Ltd.'s pipeline?

Chengdu Kanghong Biotech Co., Ltd. has 4 drugs in Phase 3, 1 in Phase 2, 1 in Phase 1. Late-stage candidates include conbercept, Fixed, Conbercept ophthalmic injection, conbercept, PRN, Placebo + Paclitaxel.

Sector hub: All tracked pharma companies